Hopp til innhold

Get alerts of updates about «Treatments for relapsing, refractory multiple myeloma: A health technology assessment»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Treatments for relapsing, refractory multiple myeloma: A health technology assessment

Project

Treatments for relapsing, refractory multiple myeloma: A health technology assessment - project description

Published Updated

Evaluation of the clinical and cost-effectiveness of the increasing number of treatments available for patients who experience relapsed or refractory multiple myeloma (RRMM).


Summary

Multiple myeloma (MM), the second most common type of blood cancer, reduces the body’s ability to fight infection and can lead to anemia, bone damage, nerve damage, kidney damage, etc. Approximately 450 Norwegians are diagnosed with myeloma annually. Because there is currently no cure for myeloma, it is important to evaluate the clinical and cost-effectiveness of the increasing number of treatments available for patients who experience relapsed or refractory multiple myeloma (RRMM).

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Arna Sue Desser, Norwegian Institute of Public Health

Project participants

Fredrik Schjesvold, Oslo University Hospital
Mats Irgen Olsen, University Hospital of North Norway
Olav Ljøsne, The norwegian Leukemia Association
Einar Haukås, Stavanger Hospital Trust - Stavanger University Hospital
Ulrikke Højslev Lund, Norwegian Institute of Public Health
Christopher James Rose, Norwegian Institute of Public Health
Gunn Eva Næss, Norwegian Institute of Public Health
Elisabet Vivianne Hafstad, Norwegian Institute of Public Health
Anna Lien Espeland, Norwegian Institute of Public Health
Liv Giske, Norwegian Institute of Public Health
Ingrid Kristine Ohm, Norwegian Institute of Public Health

Start

30.03.2020

End

30.06.2021

Status

Active

Project owner/ Project manager

Norwegian Institute of Public Health

Project manager

Arna Sue Desser